Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders

por Gooderham, M.J., Papp, K.A., Lynde, C.W.
Publicado 2018

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis

por Papp, K.A., Gooderham, M.J., Girard, G., Raman, M., Strout, V.
Publicado 2017

Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO‐INSIGHTFUL stu...

por Hong, C‐H., Papp, K.A., Lophaven, K.W., Skallerup, P., Philipp, S.
Publicado 2017

AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients wi...

por Hercogová, J., Papp, K.A., Chyrok, V., Ullmann, M., Vlachos, P., Edwards, C.J.
Publicado 2019

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting

por Papp, K.A., Gooderham, M.J., Albrecht, L.E., Raymond, M.‐A., Lynde, C.W.
Publicado 2022

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

por Gottlieb, AB, Langley, RG, Strober, BE, Papp, KA, Klekotka, P, Creamer, K, Thompson, EHZ, Hooper, M, Kricorian, G
Publicado 2012

Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF m...

por Papp, K.A., Gooderham, M., Jenkins, R., Vender, R., Szepietowski, J.C., Wagner, T., Hunt, B., Souberbielle, B.
Publicado 2018

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

por Tan, H, Gupta, P, Harness, J, Wolk, R, Chapel, S, Menter, A, Strober, B, Langley, RG, Krishnaswami, S, Papp, KA
Publicado 2013

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III stu...

por Kimball, A.B., Papp, K.A., Reich, K., Gooderham, M., Li, Q., Cichanowitz, N., La Rosa, C., Blauvelt, A.
Publicado 2019

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

por Kimball, A.B., Kerbusch, T., van Aarle, F., Kulkarni, P., Li, Q., Blauvelt, A., Papp, K.A., Reich, K., Montgomery, D.
Publicado 2019

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients...

por Papp, KA, Barber, K, Bissonnette, R, Bourcier, M, Lynde, CW, Poulin, Y, Shelton, J, Toole, J, Vieira, A, Poulin-Costello, M
Publicado 2015

Real‐world effectiveness of adalimumab in patients with moderate‐to‐severe hidradenitis suppurativa: the 1‐year SOLACE study

por Gulliver, W., Alavi, A., Wiseman, M.C., Gooderham, M.J., Rao, J., Alam, M.S., Papp, K.A., Desjardins, O., Jean, C.
Publicado 2021

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

por Papp, K.A., Blauvelt, A., Kimball, A.B., Han, C., Randazzo, B., Wasfi, Y., Shen, Y.‐K., Li, S., Griffiths, C.E.M.
Publicado 2018

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

por Papp, K.A., Barber, K., Bissonnette, R., Bourcier, M., Lynde, C.W., Poulin, Y., Shelton, J., Garces, K., Toole, J., Poulin‐Costello, M.
Publicado 2015

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years...

por Papp, K.A., Lebwohl, M.G., Puig, L., Ohtsuki, M., Beissert, S., Zeng, J., Rubant, S., Sinvhal, R., Zhao, Y., Soliman, A.M., Alperovich, G., Leonardi, C.
Publicado 2021

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies

por Merola, J.F., Papp, K.A., Nash, P., Gratacós, J., Boehncke, W.H., Thaçi, D., Graham, D., Hsu, M‐A., Wang, C., Wu, J., Young, P.
Publicado 2020

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

por Gordon, K.B., Lebwohl, M., Papp, K.A., Bachelez, H., Wu, J.J., Langley, R.G., Blauvelt, A., Kaplan, B., Shah, M., Zhao, Y., Sinvhal, R., Reich, K.
Publicado 2021

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

por Menter, A., Papp, K.A., Gooderham, M., Pariser, D.M., Augustin, M., Kerdel, F.A., Fakharzadeh, S., Goyal, K., Calabro, S., Langholff, W., Chavers, S., Naessens, D., Sermon, J., Krueger, G.G.
Publicado 2016

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

por Blauvelt, A., Papp, K.A., Sofen, H., Augustin, M., Yosipovitch, G., Katoh, N., Mrowietz, U., Ohtsuki, M., Poulin, Y., Shrom, D., Burge, R., See, K., Mallbris, L., Gordon, K.B.
Publicado 2017